Section Arrow
INTS.NASDAQ
- Intensity Therapeutics
Quotes are at least 15-min delayed:2024/06/12 12:03 EDT
Last
 4.8
-0.17 (-3.42%)
Day High 
4.9 
Prev. Close
4.97 
1-M High
5.275 
Volume 
1.03K 
Bid
4.8
Ask
4.95
Day Low
4.8 
Open
4.9 
1-M Low
Market Cap 
68.15M 
Currency USD 
P/E -- 
%Yield
10-SMA 4.91 
20-SMA 4.92 
50-SMA 4.45 
52-W High 11.44 
52-W Low 2.0101 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.10/--
Enterprise Value
68.29M
Balance Sheet
Book Value Per Share
0.71
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.5464+0.0301+5.83%-- 
LGVNLongeveron1.4097+0.5897+71.91%-- 
RNAAvidity Biosciences38.255+9.335+32.28%-- 
GERNGeron Corp5.2199+0.1299+2.55%-- 
NVAXNovavax16.63-0.095-0.57%-- 
Quotes are at least 15-min delayed:2024/06/12 12:03 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.